131 results on '"Younes, Anas"'
Search Results
2. New drugs for new targets in lymphoma.
3. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma.
4. Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma.
5. Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
6. P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL).
7. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
8. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
9. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
10. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
11. Phase II study of HCVIDD/ MA in patients with newly diagnosed peripheral T-cell lymphoma.
12. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
13. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
14. Clinical applications of genome studies.
15. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non- Hodgkin lymphoma.
16. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.
17. Phase IA/ II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non- Hodgkin or Hodgkin lymphoma.
18. Prospective phase II study of rituximab with alternating cycles of hyper- CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
19. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.
20. Long term results of a phase 2 study of vincristine sulfate liposome injection ( Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non- Hodgkin lymphomas
21. Micro RNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
22. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
23. FLUORESCENCE IN SITU HYBRIDIZATION OF LYMPHOPROLIFERATTVE MALIGNANCIES.
24. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
25. Hodgkin lymphoma risk: Role of genetic polymorphisms and gene-gene interactions in DNA repair pathways.
26. Hodgkin disease risk: Role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.
27. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism D. Buglio et al MGCD0103 in Hodgkin Lymphoma.
28. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
29. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
30. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
31. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
32. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
33. Phase 2 Study of Gemcitabine in Combination With Rituximab in Patients With Recurrent or Refractory Hodgkin Lymphoma.
34. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
35. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
36. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
37. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
38. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
39. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
40. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.
41. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.
42. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells.
43. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
44. XII. Therapeutic exploitation of autologous T-cell activation in B-cell lymphoma.
45. A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma.
46. Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
47. Functional expression of TRAIL by lymphoid and myeloid tumour cells.
48. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
49. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.
50. Polysomy of chromosome 12 in 60 patients with non-hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.